Dosimetry for therapeutic treatment of neuroblastoma by 131I-mIBG

被引：0

作者：

Sudbrock, F.

Eschner, W.

Schmidt, M.

Simon, T.

Hero, B.

Schicha, H.

机构：

[1] Univ Cologne, Nukl Med Klin & Poliklin, D-50937 Cologne, Germany

[2] Univ Cologne, Zentrum Kinderonkol & Hamatol, D-50937 Cologne, Germany

来源：

NUKLEARMEDIZIN-NUCLEAR MEDICINE | 2006年 / 45卷 / 06期

关键词：

neuroblastom; mIBG-Therapie; ganzkorperszintigraphie; SPECT dosimetrie; energiedosis;

D O I：

暂无

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Aim: Targeted radiotherapies using iodine-131 meta-iodobenzylguanidin have long been in use for treatment of stage IV neuroblastoma but reliable dosimetric data are scarce. Method: This work presents an approach to determine the whole body exposure and tumour doses delivered during therapy. Dosimetric data are reported and discussed for six treatments carried out according to the trial protocol NB2004 as it is in use in our study in the last two years. Results: Whole body exposures are found to be in the range of 1.75 to 2.5 Gy whereas tumour doses vary between 15 and 55 Gy. Conclusion: The course of action prescribed by the trial protocol allows whole body exposure as well as tumour doses to be determined routinely.

引用

页码：254 / 261

页数：8

共 50 条

[11] 131I-mIBG treatment dosimetry: dependence on the fitting expression and the role of biodosimetry
Torres-Espallardo, I.
Balaguer, J.
Montoro, A.
Sebastian, N.
Loaiza, J.
Olivas, C.
Bautista, J.
Adria, M.
Ibanez, B.
Pascual, V.
Campayo, J.
Villaescusa, J.
Canete, A.
Castel, V.
Bello, P.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S419 - S419
[12] Is there a benefit of 131I-MIBG therapy FOR in the treatment of children with stage 4 neuroblastoma?
Schmidt, M.
Simon, T.
Hero, B.
Eschner, W.
Dietlein, M.
Sudbrock, F.
Bongartz, R.
Berthold, F.
Schicha, H.
NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2006, 45 (04): : 145 - 151
[13] NURSING CARE ISSUES DURING 131I-MIBG TREATMENT FOR ADVANCE NEUROBLASTOMA
Lam, C.
Cheng, K.
Cheung, J.
PEDIATRIC BLOOD & CANCER, 2013, 60 : 186 - 186
[14] Local delivery of 131I-MIBG to treat peritoneal neuroblastoma
Kinuya, S
Li, XF
Yokoyama, K
Mori, H
Shiba, K
Watanabe, N
Shuke, N
Bunko, H
Michigishi, T
Tonami, N
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2003, 30 (09) : 1246 - 1250
[15] Local delivery of 131I-MIBG to treat peritoneal neuroblastoma
Seigo Kinuya
Xiao-Feng Li
Kunihiko Yokoyama
Hirofumi Mori
Kazuhiro Shiba
Naoto Watanabe
Noriyuki Shuke
Hisashi Bunko
Takatoshi Michigishi
Norihisa Tonami
European Journal of Nuclear Medicine and Molecular Imaging, 2003, 30 : 1246 - 1250
[16] The Therapeutic Effect of 131I-MIBG Focusing on the Lesions not Detected by a Conventional 123I-MIBG Scintigraphy in Neuroblastoma
Araki, Raita
Nishimura, Ryosei
Fujiki, Toshihiro
Inaki, Anri
Wakabayashi, Hiroshi
Noguchi, Kazuhiro
Mase, Shintaro
Kuroda, Rie
Ikawa, Yasuhiro
Maeba, Hideaki
Sakai, Seisho
Yachie, Akihiro
Kinuya, Seigo
PEDIATRIC BLOOD & CANCER, 2017, 64 : S89 - S89
[17] Dosimetric evaluation of Neuroblastoma patients submitted to 131I-MIBG
Rezio, M. T.
Ferreira, T. C.
Salgado, L.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 : S429 - S429
[18] Biodistribution of post-therapeutic versus diagnostic 131I-MIBG scans in children with neuroblastoma
Hickeson, MP
Charron, M
Maris, JM
Brophy, P
Kang, TI
Zhuang, HM
Khan, J
Nevrotski, T
PEDIATRIC BLOOD & CANCER, 2004, 42 (03) : 268 - 274
[19] ANATOMIC PATTERNS OF RELAPSE AND PROGRESSION FOLLOWING TREATMENT WITH 131I-MIBG IN METASTATIC NEUROBLASTOMA
Ben Kenan, Fishel R.
Polishchuk, A.
Haas-Kogan, D.
JOURNAL OF INVESTIGATIVE MEDICINE, 2017, 65 (01) : 143 - 143
[20] Dosimetric evidences of 131I-MIBG treatment in High Risk Neuroblastoma in VERITAS protocol
Saletti, P.
Olianti, C.
Tondo, A.
Simontacchi, G.
Belli, G.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 : S225 - S225

← 1 2 3 4 5 →